BioMarin Pharmaceutical Inc.
BMRN
Classificação em ações
#1942
BioMarin Pharmaceutical Inc. specializes in creating and bringing to market... BioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions. The company currently markets several key pharmaceutical products. Among these are Vimizim, an enzyme replacement therapy targeting mucopolysaccharidosis (MPS) IV type A, a specific lysosomal storage disorder, and Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for individuals with MPS VI. Another notable offering is Kuvan, a unique synthetic oral version of 6R-BH4, prescribed for phenylketonuria (PKU), an inherited metabolic condition. Further expanding its product portfolio, BioMarin provides Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme administered via subcutaneous injection to lower blood Phe levels. Also available are Brineura, a recombinant human tripeptidyl peptidase 1 used in treating ceroid lipofuscinosis type 2, a variant of Batten disease; Voxzogo, a daily injectable c-type natriuretic peptide analog for achondroplasia; and Aldurazyme, a refined protein mirroring the naturally occurring human enzyme alpha-L-iduronidase. Beyond its established products, BioMarin has a robust development pipeline. This includes valoctocogene roxaparvovec, an adeno-associated virus vector undergoing Phase III clinical trials for severe hemophilia A. Additionally, BMN 307, an AAV5-mediated gene therapy, is in Phase 1/2 trials, aiming to normalize blood phenylalanine levels in PKU patients, while BMN 255 is also in Phase 1/2 trials for primary hyperoxaluria. Its clientele spans specialty pharmacies, hospitals, international government health bodies, and a network of distributors and pharmaceutical wholesalers. These services reach patients and healthcare providers across the United States, Europe, Latin America, and other global markets. BioMarin maintains strategic licensing and collaborative alliances with partners such as Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. Established in 1996, the company's corporate headquarters are located in San Rafael, California.
Preço da ação
$56.16
Valor de mercado
$10.87B
Variação (1 dia)
2.73%
Variação (1 ano)
5.82%
País
US
Negociar BioMarin Pharmaceutical Inc. (BMRN)
Categoria
Healthcare
Rácio P/E de BioMarin Pharmaceutical Inc. (BMRN)
Rácio P/E em October 2026 TTM: 145.11
De acordo com os últimos relatórios financeiros e o preço das ações da BioMarin Pharmaceutical Inc., o rácio P/E atual (TTM) é 145.11. No final de 2024, a empresa tinha um P/E de 29.26.
Histórico do rácio P/E da BioMarin Pharmaceutical Inc. de 2000 a 2026
Rácio P/E no final de cada ano
| Ano | Índice P/E | Alterar |
|---|---|---|
| 2026 (TTM) | 145.11 | -62.55% |
| 2025 | 387.50 | 1,224.27% |
| 2024 | 29.26 | -72.91% |
| 2023 | 108.03 | -20.24% |
| 2022 | 135.44 | -153.72% |
| 2021 | -252.11 | -1,457.99% |
| 2020 | 18.56 | -102.92% |
| 2019 | -634.76 | 225.07% |
| 2018 | -195.27 | 46.94% |
| 2017 | -132.89 | 509.07% |
| 2016 | -21.82 | -77.64% |
| 2015 | -97.58 | -0.69% |
| 2014 | -98.26 | 78.81% |
| 2013 | -54.95 | 6.19% |
| 2012 | -51.75 | -27.73% |
| 2011 | -71.60 | -630.82% |
| 2010 | 13.49 | -100.35% |
| 2009 | -3.86K | -6,863.74% |
| 2008 | 57.14 | -126.61% |
| 2007 | -214.77 | 342.05% |
| 2006 | -48.59 | 386.32% |
| 2005 | -9.99 | 355.37% |
| 2004 | -2.19 | -65.51% |
| 2003 | -6.36 | 31.16% |
| 2002 | -4.85 | -40.63% |
| 2001 | -8.17 | -12.18% |
| 2000 | -9.30 | 0.00% |
Rácio P/E para empresas semelhantes ou concorrentes
| Empresa | Rácio P/E | Diferença do rácio P/E | País |
|---|---|---|---|
| 28.78 | -80.16% |
US
|
|
| -28.36 | -119.54% |
US
|
|
| -24.57 | -116.93% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -79.10% |
NL
|
Como interpretar um P/E Ratio?
O rácio Preço/Lucro (P/E) mede a relação entre o preço da ação de uma empresa e o lucro por ação.
Um P/E baixo mas positivo representa uma empresa com altos lucros face à sua valorização atual e pode estar subvalorizada. Um P/E negativo elevado (perto de 0) representa perdas significativas.
Empresas com P/E acima de 30 ou negativo são geralmente vistas como "ações de crescimento", significando que os investidores esperam crescimento ou rentabilidade futura.
Empresas com P/E positivo inferior a 10 são geralmente consideradas "ações de valor", ou seja, já são muito lucrativas mas com pouco potencial de crescimento.